BioSpectrum Asia|June 2020
How is CST contributing towards tackling the COVID-19 pandemic?
Cell Signaling Technology (CST) has and is rapidly expanding a portfolio of research use antibodies, proteins, and tools to build assays that can be used for creating viral and serological tests and studying mechanisms of SARS-CoV-2 infection and host-immune response. These products enable researchers around the globe to understand the biology and pathology of the virus, so their efforts to develop reliable serological tests, therapeutic treatments, and vaccines can move forward quickly. There has been an incredibly rapid effort to build tests to help fight the COVID-19 pandemic. Unfortunately, as we read in the news, speed often comes at the expense of quality. Global research efforts have to move fast, but the scientific and medical community can’t afford to waste time on assays and experiments that used poorly validated reagents, or worse yet come to an erroneous conclusion. So, CST is committed to developing new rigorously validated antibodies and protein tools to important targets of COVID-19 pathology and immunology. Validation is always important, but it is especially crucial now to ensure that reagents are accurate and reliable. At CST, we are stepping forward in solidarity with the scientific community to fight this disease the best way we know how, based on quality and scientific rigor.
You can read up to 3 premium stories before you subscribe to Magzter GOLD
Log in, if you are already a subscriber
Get unlimited access to thousands of curated premium stories and 5,000+ magazines
READ THE ENTIRE ISSUE